A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis
Status:
Unknown status
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The participation in this clinical study will last approximately 21 weeks with a 1 week
screening period and a 12 weeks treatment duration. If the study doctor finds, that the
patients disease has significantly improved he/she will enter a treatment free follow-up
period of 8 weeks. In total the study consists of 5 to 6 clinical visits (V1 - V6) and 1
telephone follow-up call.